J&J CEO Choice Likely Will Not Raise Consumer Business Profile
This article was originally published in The Tan Sheet
Executive Summary
Alex Gorsky will replace William Weldon as Johnson & Johnson CEO in April. Like his predecessor, who has led during a time of extensive OTC recalls, Gorsky’s experience with J&J comprises management of Rx pharmaceutical and medical device businesses, with no consumer background.
You may also be interested in...
McNeil Recalls Liquid Infants’ Tylenol With Dosing Device Problem
McNeil Consumer Healthcare recalls an Infants’ Tylenol product that returned to market in November, after receiving consumer complaints about a problem with the SimpleMeasure dosing device system. The recall marks a misstep in the J&J subsidiary’s comeback from OTC quality control issues.
J&J Fills Consumer Chief Post, Promotes Likely CEO Candidates
In a slew of appointments, Johnson & Johnson names a successor for Colleen Goggins as worldwide consumer group chairman and positions two senior executives as likely candidates to be the next CEO.
Andrx Concerta
Firm has pending ANDAs for generic versions of McNeil's Rx Concerta (methylphenidare hydrochloride) extended-release tablets in 18, 27, 36 and 54 mg formulations. McNeil's exclusivity for the pediatric hyperactivity deficit disorder drug was set to expire March 17, and the firm has filed a citizen petition with FDA "that affects the timing of, and potentially the approval criteria for, ANDA approvals relating to generic Concerta," according to Andrx. McNeil put 300 sales reps behind the drug in 2000 (1"The Tan Sheet," April 24, 2000, In Brief)...